Prospector
Profile
07.1379
|
| |
| Alliance Pharmaceutical Corp. |
NAICS |
541710 |
| 4660 La Jolla Village Drive
San Diego, CA 92122 |
Description |
Biotechnology |
| (858) 410-5200 |
Employees |
1 |
| http://www.allp.com/ |
Revenue |
(mil) |
0.5730 |
| |
Income |
(mil) |
-4.0930 |
| |
Assets |
(mil) |
1.0690 |
| |
Liability |
(mil) |
13.7650 |
| |
(for the year ended 2007-06-30) |
| |
|
Category:
Default
|
| |
|
Event:
As of September 27, 2007, Alliance Pharmaceutical Corp. is in default under Senior Convertible Promissory Notes in the aggregate principal and interest amount of approximately $12 million. Alliance is continuing to seek additional financing for the purpose of funding its continuing operations through June 2008.
|
| |
|
Intellectual Property:
The Company continues to pursue patent protection in the U.S. and in foreign countries that are important for future endeavors. In the U.S., Europe, Japan, Canada and other countries, Alliance has a patent position on a second generation of stable fluorocarbon emulsions for any use including IN VIVO oxygen delivery. Alliance has a recent patent application covering the specific formulation of AF0144 to further protect its position from generic competition. AF0144 is a new chemical entity and, once approved, may have an additional five-year extension to the patents. [SEC Filing 10-KSB 06-30-07]
|
| |
|
Description:
Alliance Pharmaceutical is a research and development company focused on transforming innovative scientific discoveries into novel therapeutic and diagnostic agents.
|
| |
|
Officers:
Duane Roth (Chair & CEO); B. Jack DeFranco (Pres. & COO); Edward Hall (CFO); Theodore D. Roth (Dir.); Pedro Cuatrecasas, M.D. (Dir.); Carroll O. Johnson (Dir.); Stephen M. McGrath (Dir.); Jean Riess, Ph.D. (Dir.)
|
| |
|
Auditor:
KMJ Corbin & Company LLP
|
| |
|
Securities:
50,848,283 common shares outstanding as of September 24, 2007.
|
| |
| |
| |
| return to main page |
